ABSI Stock — Absci Corporation: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop.

Source: 10-K FY2025 via SEC EDGAR

Share price

$8.50

Market cap

$1,468.2M

Cash

$218.3M

Enterprise value

$1,249.9M

Balance sheet

Cash	$218.3M
Debt	$0.0M
Net cash	$218.3M
Enterprise value	$1,249.9M
Basic shares	172.8M shares
Fully diluted shares	203.8M shares
Fully diluted market cap	$1,732.0M
Cash per share	$1.26
Quarterly burn	$27.6M
Cash runway	7.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.

Share structure

Common

171.6M

Pre-funded warrants

0.0M

Options

23.1M

RSUs

4.5M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

4.5M

FDSO

203.8M

Cap table as of 2026-06-30.

Price history

Loading ABSI daily closes…

Loading price history…

Next catalyst

ABS-201 · Est. Nov 14, 2026 · half midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 14, 2026 Now half midpoint	ABS-201 HEADLINE Phase 1/2a in pattern hair loss, interim proof-of-concept · NCT07317544	Phase 1/2a	pattern hair loss	H2 2026
GUIDEDEst. Mar 1, 2027 in 7 wks guidance midpoint	ABS-201 HEADLINE Phase 1/2a in pattern hair loss, full proof-of-concept · NCT07317544	Phase 1/2a	pattern hair loss	early 2027
Aug 12 - Sep 23 in 21 mo	SAD IV Dose 1 - 150mg ABS201 IV Single Dose	Phase 1/2	Androgenetic Alopecia (AGA); Healthy Volunteers - Male and Female	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ABS-201

Phase 1 · Active Modality: antibody

Target PRLR (prolactin receptor)

Indications

pattern hair loss (PHL) (Phase 1)
endometriosis (Phase 2)

Catalysts

— Q4 2026
— H2 2027

Status note Anti-PRLR antibody with extended half-life. HEADLINE Phase 1/2a trial in PHL ongoing (interim Phase 1 data reported June 2026); Phase 2 trial in endometriosis anticipated to initiate Q4 2026.

ABS-202

Preclinical · Active Modality: antibody

Target PRLR (prolactin receptor)

Indications

undisclosed immunology and inflammation indication (Preclinical)

Status note Second novel anti-PRLR antibody program, designed via generative AI platform; indication undisclosed.

ABS-101

Stage not disclosed · Active Modality: antibody

Target TL1A

Indications

inflammatory bowel disease (IBD) (Stage not disclosed)

Status note Mentioned only in the 10-K competitive landscape section as a TL1A-targeting candidate; stage not stated in the filings reviewed.

ABS-301

Preclinical · Active

Indications

oncology (indication not specified) (Preclinical)

Status note Potential first-in-class oncology asset discovered through the company's reverse immunology platform; per 10-K business section.

ABS-501

Preclinical · Active

Target HER2

Indications

HER2-expressing cancers (indication not specified) (Preclinical)

Status note Potentially differentiated HER2 program; per 10-K business section.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SAD IV Dose 1 - 150mg ABS201 IV Single Dose
Lead indication	Androgenetic Alopecia (AGA)
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07317544	Phase 1/2	Recruiting	Sponsor	Absci Pty Ltd.	—	Androgenetic Alopecia (AGA); Healthy Volunteers - Male and Female	H2 2026 Est. Nov 14, 2026 · half midpoint early 2027 Est. Mar 1, 2027 · guidance midpoint

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Absci Pty Ltd. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
BVF Partners	2,361,674	+2,361,674	0.70%	2026-08-14
Baker Bros. Advisors	2,134,803	no change	0.12%	2026-08-14
Casdin Capital	973,260	no change	0.56%	2026-08-14
Ikarian Capital	353,772	+353,772	0.67%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ABSI — Absci Corporation ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ABSI — Absci Corporation